Partial restoration of the lipopolysaccharide-induced proliferative response in splenic B cells from C3H/HeJ mice. 1986

K Kuus-Reichel, and R J Ulevitch

C3H/HeJ mice are hyporesponsive to the biologic effects of bacterial lipopolysaccharide (LPS), and their splenic B cells do not proliferate after exposure to LPS. The molecular basis of this hyporesponsiveness is unknown but it may result from defective membrane signal transduction after LPS binding. To examine this possibility, we added bioactive compounds in combination with LPS to C3H/HeJ B cell cultures in order to bypass the putative defect. The addition of PMA, monensin, or ionomycin, either alone or in combination, had no effect on C3H/HeJ B cell responses to LPS. In contrast, the addition of trypsin together with LPS resulted in a partial restoration of the proliferative response in C3H/HeJ splenic B lymphocytes. The maximal C3H/HeJ B cell response varied from 25 to 60% of the C3Heb/FeJ (LPS responder) B cell response. The trypsin-mediated enhancement of the LPS response was abrogated by pretreatment of the trypsin with the trypsin inhibitors DFP or TLCK. Pretreatment of the LPS with polymyxin B, which blocks lipid A-dependent reactions, also abrogated the trypsin effect. Because the C3H/HeJ B cell responds to all other B cell mitogens, we suggest that the defect is in an LPS-specific step and that the action of trypsin results in the restoration of the missing signal. At the present time the identity of this signal is not known, but the experiments described in this report provide a unique model to elucidate the basis of LPS hyporesponsiveness in splenic B cells from C3H/HeJ mice.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D008985 Monensin An antiprotozoal agent produced by Streptomyces cinnamonensis. It exerts its effect during the development of first-generation trophozoites into first-generation schizonts within the intestinal epithelial cells. It does not interfere with hosts' development of acquired immunity to the majority of coccidial species. Monensin is a sodium and proton selective ionophore and is widely used as such in biochemical studies. Coban,Monensin Monosodium Salt,Monensin Sodium,Monensin-A-Sodium Complex,Rumensin,Monensin A Sodium Complex
D011112 Polymyxin B A mixture of polymyxins B1 and B2, obtained from BACILLUS POLYMYXA strains. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for treatment of infections with gram-negative bacteria, but may be neurotoxic and nephrotoxic. Aerosporin,Polymyxin B Sulfate
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D004987 Ethers Organic compounds having two alkyl or aryl groups bonded to an oxygen atom, as in the formula R1–O–R2.
D005260 Female Females
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

K Kuus-Reichel, and R J Ulevitch
April 1993, Immunobiology,
K Kuus-Reichel, and R J Ulevitch
September 1990, Nichidai koku kagaku = Nihon University journal of oral science,
K Kuus-Reichel, and R J Ulevitch
October 1981, Experimental hematology,
K Kuus-Reichel, and R J Ulevitch
January 1985, Proceedings of the Western Pharmacology Society,
K Kuus-Reichel, and R J Ulevitch
March 1997, Brain research,
K Kuus-Reichel, and R J Ulevitch
March 1977, Journal of immunology (Baltimore, Md. : 1950),
K Kuus-Reichel, and R J Ulevitch
January 1988, Journal of leukocyte biology,
Copied contents to your clipboard!